Moonshots with Peter Diamandis

Podbit · Moonshots with Peter Diamandis

Michael Kratsios on the New Golden Age of American Science | EP #276

Explore episode Aug 4, 2026
Science
XPRIZE and the Power of Prizes: $600M That Drove $30B in R&D

Michael Kratsios on the New Golden Age of American Science … · Aug 4, 2026 Science

XPRIZE has launched $600 million in prizes and catalyzed $30 billion in R&D. The Golden Age Report explicitly endorses prize challenges, advanced market commitments, and pay-for-results models as alternatives to traditional grants — with the administration eyeing prizes in the $100 million range for major national challenges.

Where this was said

Prizes, XPRIZE, and the Future of Pay-for-Results Science

At 47:00 · chapter starts 45:55

With the Golden Age Report explicitly endorsing prize challenges and advanced market commitments, Peter steps into his home turf: over 30 years, XPRIZE has launched $600 million in prize competitions and driven approximately $30 billion in R&D — a roughly 50:1 leverage ratio on prize capital. He pitches Kratsios on the idea of 10 $1 billion prizes focused on the nation's most important challenges, including one targeting longevity. Kratsios is enthusiastic but pragmatic: the federal budget can absorb prizes in the $100 million range for sufficiently significant challenges, but $1 billion for a single prize is a stretch for the current fiscal environment. Peter then introduces the $101 million XPRIZE Healthspan — the organization's largest-ever prize, with 830 competing teams — as an example of what's achievable, arguing that reversing aging by 20 functional years would be the single highest-impact intervention on the US economy.

Similar podbits

Science
The Placebo Effect Is Not Fake — It Just Belongs to the Story, Not the Drug

#403 ‒ Peptides: separating scientific promise from marketi… · Aug 10, 2026 Science

Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.